Pharmascience expands CDMO services with new business unit

MONTREAL — Last Fall, Pharmascience, a pharmaceutical company, announced a major $120 million sterile injectable manufacturing facility expansion at its Candiac site. Following this, the company now announces the expansion of its contract development and manufacturing organization (CDMO) services with the creation of a new business unit dedicated to injectable products.

This new business unit will help accelerate production and achieve Pharmascience’s growth objectives by enabling the company to offer its R&D, formulation and manufacturing services to external pharmaceutical partners. It will focus more specifically on injectable products, with a mandate to offer CDMO services to biotech companies and those with complex injectable product development or manufacturing needs.

“With a vision to continue our expansion while supporting local development and manufacturing, we see a tremendous opportunity to expand our services to meet the needs of a growing pharmaceutical client base, whose complex injectable product supply requirements can be met by the extraordinary expertise of the Pharmascience team. Creating our new CDMO business unit represents an excellent way to maximize the value of our research and development efforts and the value of every unit we produce at our Candiac plant,” says Martin Arès, CEO of Pharmascience.

Alongside the creation of this new CDMO business unit, Pharmascience is pleased to welcome John Foy as General Manager, CDMO since February.

Pharmascience hopes that by 2026, the company will have invested over $120 million to expand its facilities and more than triple its capacity with new equipment. This will enable the company to support more patients, with annual production rising to more than 20 million units. They say the expansion is already well underway and will also enable Pharmascience to compete with international players and broaden its client base with a new range of products and services.